Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial

EORTC-62092 is an open-label, randomized, phase 3 study done in 31 research institutions, hospitals, and cancer centers in 13 countries in Europe and North America. Adults with a primary retroperitoneal sarcoma that was operable and suitable for radiotherapy who had not been previously treated were randomly assigned to receive surgery alone or preoperative radiotherapy followed by surgery

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

The study assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with advanced tumors. Objective responses were observed in 30 (29%) of 102 patients in the tT MB-high group and 43 (6%) of 688 in the non-MB- high group.

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial

GetUG-AFU 17 was a randomized, open-label, multicentre, phase 3 trial done at 46 French hospitals. 5-year event-free survival was 92% in the adjuvant radiotherapy group. Acute grade 3 or worse toxic effects occurred in six (3%) of 212 patients.

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

Adjuvant radiotherapy has been shown to halve the risk of biochemical progression for patients with high-risk disease after radical prostatectomy. Salvage radiotherapy did not meet trial-specified criteria for non-inferiority. 5-year freedom from biochemical progression was 86% (95% CI 81–92) in the adjuvant radiotherapy group versus 87% (82–93%) in the salvage radiotherapy groups.

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Carfilzomib, a next-generation proteasome inhibitor, in combination with lenalidomide and dexamethasone has shown promising efficacy in phase 2 trials. The VRd triplet regimen remains the standard of care for induction therapy for patients with newly diagnosed multiple myeloma.

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

The study investigated COVID-19 risk according to tumor type and patient demographics in patients with cancer in the UK. 319 out of 1044 patients died with a cause of death recorded as due to the disease. The all-cause case–fatality rate in patients. with cancer after SARS-CoV

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

CTDNA testing might provide an assessment of the genomic profile of advanced cancer without the need to repeat tumor biopsy. We did an open-label, multicohort, phase 2a, platform trial of ctDNA testing in 18 UK hospitals. Patients were recruited into four parallel treatment cohorts matched to mutations identified in ct DNA.

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Addition of atezolizumab to trastuzumab emtansine might potentiate anticancer immunity and enhance the HER2-targeted cytotoxic activity. The KATE2 study is a randomised, double-blind, placebo-controlled, phase 2 study at 68 centres in nine countries. The addition of atezlizumb to trastuzumab emtansine did not show a clinically meaningful improvement in progression-free survival.

Departments

Recent Posts